View in EDS HTML Full Text PDF Full Text

Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models.

Saved in:
Bibliographic Details
Title: Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models.
Authors: Pakola SA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Ojala N; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., van der Heijden M; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Hemminki O; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Urology, Helsinki University Hospital, Helsinki, Finland., Kanerva A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland., Mustonen H; Department of Surgery, Translational Cancer Medicine Research Program and ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Puolakkainen P; Department of Surgery, Translational Cancer Medicine Research Program and ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Seppänen H; Department of Surgery, Translational Cancer Medicine Research Program and ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi.; TILT Biotherapeutics Ltd, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. akseli.hemminki@helsinki.fi.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Jun 04; Vol. 74 (7), pp. 234. Date of Electronic Publication: 2025 Jun 04.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40465005
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pakola+SA%22">Pakola SA</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Ojala+N%22">Ojala N</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Kudling+TV%22">Kudling TV</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Clubb+JHA%22">Clubb JHA</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Jirovec+E%22">Jirovec E</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22van+der+Heijden+M%22">van der Heijden M</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Arias+V%22">Arias V</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Haybout+L%22">Haybout L</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Basnet+S%22">Basnet S</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Grönberg-Vähä-Koskela+S%22">Grönberg-Vähä-Koskela S</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Quixabeira+DCA%22">Quixabeira DCA</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Santos+JM%22">Santos JM</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Cervera-Carrascon+V%22">Cervera-Carrascon V</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Hemminki+O%22">Hemminki O</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Urology, Helsinki University Hospital, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Kanerva+A%22">Kanerva A</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Mustonen+H%22">Mustonen H</searchLink>; Department of Surgery, Translational Cancer Medicine Research Program and ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Puolakkainen+P%22">Puolakkainen P</searchLink>; Department of Surgery, Translational Cancer Medicine Research Program and ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Seppänen+H%22">Seppänen H</searchLink>; Department of Surgery, Translational Cancer Medicine Research Program and ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Hemminki+A%22">Hemminki A</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi.; TILT Biotherapeutics Ltd, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. akseli.hemminki@helsinki.fi.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2025 Jun 04; Vol. 74 (7), pp. 234. <i>Date of Electronic Publication: </i>2025 Jun 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40465005
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00262-025-04072-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 234
    Titles:
      – TitleFull: Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pakola SA
      – PersonEntity:
          Name:
            NameFull: Ojala N
      – PersonEntity:
          Name:
            NameFull: Kudling TV
      – PersonEntity:
          Name:
            NameFull: Clubb JHA
      – PersonEntity:
          Name:
            NameFull: Jirovec E
      – PersonEntity:
          Name:
            NameFull: van der Heijden M
      – PersonEntity:
          Name:
            NameFull: Arias V
      – PersonEntity:
          Name:
            NameFull: Haybout L
      – PersonEntity:
          Name:
            NameFull: Basnet S
      – PersonEntity:
          Name:
            NameFull: Grönberg-Vähä-Koskela S
      – PersonEntity:
          Name:
            NameFull: Quixabeira DCA
      – PersonEntity:
          Name:
            NameFull: Santos JM
      – PersonEntity:
          Name:
            NameFull: Cervera-Carrascon V
      – PersonEntity:
          Name:
            NameFull: Hemminki O
      – PersonEntity:
          Name:
            NameFull: Kanerva A
      – PersonEntity:
          Name:
            NameFull: Mustonen H
      – PersonEntity:
          Name:
            NameFull: Puolakkainen P
      – PersonEntity:
          Name:
            NameFull: Seppänen H
      – PersonEntity:
          Name:
            NameFull: Hemminki A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 06
              Text: 2025 Jun 04
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0851
          Numbering:
            – Type: volume
              Value: 74
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Cancer immunology, immunotherapy : CII
              Type: main
ResultId 1